KLSE:TMCLIFE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

TMC Life Sciences Berhad

Market Cap

RM1.0b

Last Updated

2021/07/30 17:22 UTC

Data Sources

Company Financials

Executive Summary

TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has TMC Life Sciences Berhad's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TMCLIFE is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: TMCLIFE's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.4%

TMCLIFE

-2.4%

MY Healthcare

-1.9%

MY Market


1 Year Return

16.5%

TMCLIFE

7.0%

MY Healthcare

-1.5%

MY Market

Return vs Industry: TMCLIFE exceeded the MY Healthcare industry which returned 9.4% over the past year.

Return vs Market: TMCLIFE exceeded the MY Market which returned -0.7% over the past year.


Shareholder returns

TMCLIFEIndustryMarket
7 Day-2.4%-2.4%-1.9%
30 Day-4.0%1.0%-1.3%
90 Day-16.7%4.4%-6.6%
1 Year16.8%16.5%7.8%7.0%2.1%-1.5%
3 Year-19.3%-20.0%-0.9%-3.2%-3.7%-12.8%
5 Year-29.8%-30.6%-9.8%-13.1%8.6%-9.6%

Long-Term Price Volatility Vs. Market

How volatile is TMC Life Sciences Berhad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TMC Life Sciences Berhad undervalued compared to its fair value and its price relative to the market?

65.61x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TMCLIFE (MYR0.6) is trading above our estimate of fair value (MYR0.03)

Significantly Below Fair Value: TMCLIFE is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TMCLIFE is poor value based on its PE Ratio (65.6x) compared to the MY Healthcare industry average (56.8x).

PE vs Market: TMCLIFE is poor value based on its PE Ratio (65.6x) compared to the MY market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TMCLIFE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TMCLIFE is good value based on its PB Ratio (1.4x) compared to the MY Healthcare industry average (3x).


Future Growth

How is TMC Life Sciences Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TMC Life Sciences Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has TMC Life Sciences Berhad performed over the past 5 years?

-44.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TMCLIFE has a high level of non-cash earnings.

Growing Profit Margin: TMCLIFE's current net profit margins (8.7%) are lower than last year (15.2%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TMCLIFE's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: TMCLIFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TMCLIFE had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Healthcare industry average (-7.8%).


Return on Equity

High ROE: TMCLIFE's Return on Equity (2.1%) is considered low.


Financial Health

How is TMC Life Sciences Berhad's financial position?


Financial Position Analysis

Short Term Liabilities: TMCLIFE's short term assets (MYR185.9M) exceed its short term liabilities (MYR69.9M).

Long Term Liabilities: TMCLIFE's short term assets (MYR185.9M) exceed its long term liabilities (MYR108.4M).


Debt to Equity History and Analysis

Debt Level: TMCLIFE's debt to equity ratio (10.6%) is considered satisfactory.

Reducing Debt: TMCLIFE's debt to equity ratio has increased from 0.5% to 10.6% over the past 5 years.

Debt Coverage: TMCLIFE's debt is well covered by operating cash flow (21.5%).

Interest Coverage: TMCLIFE earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is TMC Life Sciences Berhad current dividend yield, its reliability and sustainability?

0.28%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TMCLIFE's dividend (0.28%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (1.49%).

High Dividend: TMCLIFE's dividend (0.28%) is low compared to the top 25% of dividend payers in the MY market (4.17%).


Stability and Growth of Payments

Stable Dividend: TMCLIFE is not paying a notable dividend for the MY market, therefore no need to check if payments are stable.

Growing Dividend: TMCLIFE is not paying a notable dividend for the MY market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TMCLIFE is not paying a notable dividend for the MY market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TMCLIFE's dividend in 3 years as they are not forecast to pay a notable one for the MY market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Wan Binti Wan Mohd Abdullah Yaakob (37 yo)

2.33yrs

Tenure

RM1,090,906

Compensation

Ms. Wan Nadiah Binti Wan Mohd Abdullah Yaakob has been the Group Chief Executive Officer of TMC Life Sciences Berhad since February 01, 2019. Ms. Binti Wan Mohd Abdullah Yaakob has been Executive Director ...


CEO Compensation Analysis

Compensation vs Market: Wan's total compensation ($USD257.32K) is above average for companies of similar size in the MY market ($USD192.52K).

Compensation vs Earnings: Insufficient data to compare Wan's compensation with company performance.


Leadership Team

Experienced Management: TMCLIFE's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: TMCLIFE's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TMC Life Sciences Berhad's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TMC Life Sciences Berhad
  • Ticker: TMCLIFE
  • Exchange: KLSE
  • Founded: 1994
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: RM1.045b
  • Shares outstanding: 1.74b
  • Website: https://www.tmclife.com

Location

  • TMC Life Sciences Berhad
  • C-13-09 Sunway Nexis
  • No. 1, Jalan PJU 5/1
  • Petaling Jaya
  • Selangor
  • 47810
  • Malaysia

Listings


Biography

TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. It operates Thomson Hospital Kota Damansara (THKD), a 205-bedded medical center located in Selangor. The c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/30 17:22
End of Day Share Price2021/07/30 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.